Incannex Healthcare is a clinical-stage cannabinoid and psychedelic medicine developer.
Incannex
Incannex is working with Dr Paul Liknaitzky and the team at Monash University to develop psilocybin-assisted therapy for generalized anxiety disorder (GAD). The research group recently received approval to conduct the worlds first Phase II study using psilocybin to treat GAD. The trial has enlisted 72 participants making it the largest trial with psychedelic’s in Australia to date.
Activities
B2B
B2C
Pharmaceutical
Drug Discovery
Explore more company info with a Tree membership
📰 Weekly newsletter about the business of psychedelics
📈 Extended company information (analyst view, fundraising, revenue numbers)
🪄 Priority company page updates